Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease

被引:0
|
作者
Darbhanga, Jake [1 ]
Krulikowski, Kiarra [1 ]
Riskin, Suzanne I. [1 ]
机构
[1] Nova Southeastern Univ, Dr Kiran C Patel Coll Osteopath Med, Clearwater, FL 33759 USA
关键词
nonalcoholic fatty liver; nafld treatments; nash treatments; nafld; fatty liver; nafld diagnosis; drugs for nash; nonalcoholic fatty liver disease (nafld); fatty liver disease;
D O I
10.7759/cureus.47821
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The obesity epidemic has pushed fatty liver disease, which consists of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, to the forefront of the 21st century. Disease identification can be done invasively with a liver biopsy or noninvasively through elastography and measurements of biomarkers, such as the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) liver enzymes. Presently, there are no FDA-approved drugs on the market to treat the disease. Alternative medicinal treatments have been investigated, which include altering the intestinal microbiota and consuming anti-inflammatory, herbalbased, vitamin-based, and plant-based medications, in addition to following a healthy lifestyle. In this study, multiple databases were used to identify articles pertaining to fatty liver disease (FLD). Databases included Biomedical Reference Collection: Comprehensive, Cumulative Index of Nursing and Allied Health (CINAHL), Google Scholar, and PubMed. All articles gathered from the databases were peer-reviewed and less than 10 years old to ensure the credibility of the work and recent information regarding the disease. A total of 13 articles were used to gather information for this review. All articles were confirmed to be peerreviewed by checking them with Ulrich's web. In all 13 peer-reviewed articles, the diagnosis of FLD was most commonly done by analyzing ALT and AST liver enzymes and lipid profiles. Liver ultrasound, liver FibroScan, and liver biopsy served as other tools used for detecting the presence of FLD. It was observed that anti-inflammatory, herbal-based, vitamin-based, and plant-based medications and healthy gut microbiota had beneficial and therapeutic effects in treating FLD when coupled with healthy lifestyle changes. All medicinal treatments were found to lower the ALT and AST liver enzymes, lipid profiles (total cholesterol, triglycerides, low-density lipoprotein), and liver steatosis scores in studies where ultrasound was used before and after treatment. Further investigation is needed to fully understand the mechanisms behind the therapeutic effects of treating FLD; however, the medicinal treatments discussed in this review show promising prospects for treating the disease. The therapeutic effects of anti-inflammatory, herbal-based, vitamin-based, and plant-based medications and living a healthy lifestyle were seen in lower levels of liver enzymes, improved lipid profiles, and lower steatosis scores, with no reported side effects on subjects. The treatment options studied may have beneficial impacts in treating FLD patients and may be used in the development of future medications to combat the disease.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    [J]. HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [22] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    [J]. INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [23] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    [J]. ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [24] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    [J]. LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [25] Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease
    Lee, Yong-ho
    Kim, Seung Up
    [J]. HEPATOLOGY INTERNATIONAL, 2020, 14 (01) : 5 - 7
  • [26] Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease
    Yong-ho Lee
    Seung Up Kim
    [J]. Hepatology International, 2020, 14 : 5 - 7
  • [27] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [28] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    [J]. CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [29] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    [J]. OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [30] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986